{
  "created_at": "Wed Jun 23 20:35:2 +0000 2021",
  "id_str": "1407771234595639300",
  "full_text": "Some have raised concerns about how effective Sinovac is against the delta variant. In April we wrote about how China's vaccine compares to its competitors https://t.co/jsr5iXMnft",
  "display_text_range": [
    0,
    179
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/jsr5iXMnft",
        "expanded_url": "https://econ.st/2SSxfLk",
        "display_url": "econ.st/2SSxfLk",
        "indices": [
          156,
          179
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 42,
  "favorite_count": 68,
  "possibly_sensitive": false,
  "original_created_at": "Wed Jun 23 18:43:12 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "シノバックスはデルタ・バリアントにどれだけ効果があるのかという懸念もあります。4月に私たちは、中国のワクチンが競合他社と比べてどうなのかについて書いた https://t.co/jsr5iXMnft"
    },
    {
      "locale": "zh",
      "full_text": "有些人对Sinovac对delta变体的效果提出了担忧。在4月份，我们写了关于中国的疫苗与它的竞争对手相比如何https://t.co/jsr5iXMnft"
    },
    {
      "locale": "zh-Hant",
      "full_text": "有些人對Sinovac對delta變體的效果提出了擔憂。在4月份，我們寫了關於中國的疫苗與它的競爭對手相比如何https://t.co/jsr5iXMnft"
    }
  ]
}